Company profile: iBio
1.1 - Company Overview
Company description
- Provider of AI-driven drug discovery and antibody therapeutic development solutions, including a discovery platform to validate difficult targets and develop antibody therapeutics; patented Epitope Engineering Engine; fully human antibody library; StableHu Antibody Optimizer; EngageTx CD3 T-cell engager panel; and a pipeline of immuno-oncology and other therapeutic candidates.
Products and services
- Discovery Platform: Modular AI technology stack that validates difficult targets and engineers antibody therapeutics for pharmaceutical applications
- Epitope Engineering Engine: Patented technology that steers antibody discovery to specific binding sites on target proteins for epitope-directed binding
- Therapeutic Candidates: AI-driven pipeline of immuno-oncology targets and other therapeutic candidates developed using AI-driven drug discovery for antibody therapeutics
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to iBio
Kezar Life Sciences
HQ: United States
Website
- Description: Provider of drug discovery and development focused on protein homeostasis, offering Zetomipzomib (KZR-616), a selective immunoproteasome inhibitor for autoimmune diseases via immune modulation without direct immunosuppression, and KZR-261, a first-in-class Sec61 translocon inhibitor for advanced/metastatic solid tumors that blocks key secreted proteins.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kezar Life Sciences company profile →
Kynos Therapeutics
HQ: United Kingdom
Website
- Description: Provider of small-molecule KMO inhibitor therapeutics for inflammation, immunity, and metabolism. Offers KNS366, a Phase I KMO inhibitor designed to reduce elevated 3-HK to prevent tissue damage and immune dysregulation during inflammation, and a portfolio targeting acute and chronic inflammatory disorders, including acute kidney injury and acute pancreatitis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kynos Therapeutics company profile →
Talaris Therapeutics
HQ: United States
Website
- Description: Provider of biotechnology engaged in developing innovative cellular therapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Talaris Therapeutics company profile →
PvP Biologics
HQ: United States
Website
- Description: Provider of a therapeutic oral enzyme for celiac disease, developing KumaMax to break down the immuno-reactive parts of gluten in the stomach to help reduce symptoms and intestinal damage.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full PvP Biologics company profile →
Blade Therapeutics
HQ: United States
Website
- Description: Provider of discovery-stage drug development focused on oral, small-molecule therapies for fibrotic and neurodegenerative diseases, including cudetaxestat—a Phase 2-ready, non-competitive autotaxin inhibitor for idiopathic pulmonary fibrosis; BLD-2184—an IND-ready candidate for neurodegenerative diseases; a class of autotaxin inhibitors; and calpain inhibitors targeting dimeric calpains.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Blade Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for iBio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to iBio
2.2 - Growth funds investing in similar companies to iBio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for iBio
4.2 - Public trading comparable groups for iBio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →